-
2024-514824-18-00
4
2021-09-16
chronic lymphocytic leukemia/small lymphocytic lymphoma
-
2024-512982-15-00
5
2021-06-28
BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
-
2024-516623-14-00
4
2021-03-17
EBV+ primary imunodeficiency lymphoproliferative disease (LPD)
-
2024-516649-38-00
5
2020-12-01
Recurrent ovarian, fallopian tube or primary peritoneal cancer
-
2023-510515-19-00
5
2020-11-27
Higher-risk-myelodysplastic syndromes
-
2024-519007-10-00
10
2020-10-22
Locally advanced stage II/III rectal cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-510433-29-00
5
2020-09-24
Favorable-intermediate-risk Acute Myeloid Leukemia
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2023-506914-32-00
4
2020-05-05
Pan tumor
-
2023-505901-17-00
5
2020-04-24
Acute Myeloid Leukemia (LMA) with FLT3 mutation
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-509699-41-00
9
2019-11-22
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
-
2023-510516-39-00
4
2019-10-30
Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2023-504880-18-00
9
2018-04-18
Neuroblastoma (NBL)
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-516078-31-00
10
2015-05-05
Recurrent and Primary Refractory Ewing Sarcoma
-
2022-501257-36-00
9
2015-03-19
Treatment of advanced melanoma, or advanced, relapsed or
refractory PD